Researchers Think COVID-19 May Increase Parkinson’s Risk, Pointing to Need for Detailed Record-keeping

Researchers Think COVID-19 May Increase Parkinson’s Risk, Pointing to Need for Detailed Record-keeping
4.8
(4)

Although there isn’t currently sufficient evidence to draw definitive conclusions, it is possible that people who survive COVID-19 may be at increased risk of Parkinson’s disease, researchers from Brazil argued in a recent paper.

More research is needed to examine this idea, which points to a need for detailed record-keeping by healthcare systems during and after the  pandemic.

The paper, “COVID-19 and Parkinson’s Disease: Are We Dealing with Short-term Impacts or Something Worse?” was published in the Journal of Parkinson’s Disease (JPD).

It is unclear exactly what causes Parkinson’s disease; most likely a combination of genetic and environmental factors contribute to some extent. One idea put forward is that Parkinson’s could be initiated or modulated by infections. Theoretically, this could either be due to direct effects (e.g., a virus infecting and killing brain cells), or indirect effects (e.g., an infection triggering inflammation in the brain).

This idea is far from proven: “We acknowledge that further research is needed to better elucidate the role of viruses in the pathogenesis of PD [Parkinson’s disease],” researchers wrote.

Nonetheless, there are some lines of evidence that support the hypothesis. For example, research in mice has suggested that infection with some strains of influenza can trigger changes in the brain similar to those seen in Parkinson’s. Additionally, people born during or around the 1918 influenza pandemic (colloquially mischaracterized as the “Spanish flu”) were more than twice as likely to develop Parkinson’s as people born in the decades before or after that  pandemic.

Previous research also has shown that some people with Parkinson’s have antibodies against coronaviruses in the fluid around the brain. (Notably, this previous research was not examining SARS-CoV-2, the virus that causes COVID-19, but was looking at the coronavirus family in general.)

Based on these previous findings, the researchers behind the new paper suggest that COVID-19 infection may increase Parkinson’s risk.

While it is important to note that research into COVID-19 is still in its infancy, there is some emerging evidence specific to COVID-19 that supports this idea. For example, loss of the sense of smell is a well-known early symptom of Parkinson’s, and also has been reported to be a common symptom of COVID-19. Theoretically, this could suggest the virus is able to infect the parts of the central nervous system (CNS) that are necessary for processing smell (the olfactory pathway) and, from there, could spread elsewhere in the brain.

“The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains the respiratory nuclei responsible for breathing rhythm,” study author Carla Alessandra Scorza, PhD, of the Federal University of São Paulo, said in a press release.

Preliminary evidence that people with COVID-19 sometimes have neurological symptoms supports the notion that the virus could get into the brain, as does an early report describing brain inflammation in an individual with COVID-19.

“Although it is obviously too early to know what the long term consequences of COVID-19 will be on the brain, the clinical psychiatry and neurology research communities definitely need to be vigilant in monitoring how those who recover from moderate and severe COVID-19 fare in the future,” said Patrik Brundin, MD, PhD, co-editor-in-chief of the JPD. Brundin was not involved in writing the paper.

This will require strategies for monitoring COVID-19 survivors, even after the pandemic itself has subsided.

“For example,” the researchers wrote, “health systems should keep accurate medical records (clinical and imaging biomarkers) to aid specialists and researchers to address the long-term deleterious effects of SARS-CoV-2 on CNS (and their potential association with neurodegenerative disorders such as PD) in the coming years.”

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 208
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • alpha-synuclein, therapeutic strategy
  • AXO-Lenti-PD trial update
  • Ongentys trial data
  • Ongentys

How useful was this post?

Click on a star to rate it!

Average rating 4.8 / 5. Vote count: 4

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?